Cargando…

The molecular pharmacology of glucagon agonists in diabetes and obesity

Within recent decades glucagon receptor (GcgR) agonism has drawn attention as a therapeutic tool for the treatment of type 2 diabetes and obesity. In both mice and humans, glucagon administration enhances energy expenditure and suppresses food intake suggesting a promising metabolic utility. Therefo...

Descripción completa

Detalles Bibliográficos
Autores principales:	Novikoff, Aaron, Müller, Timo D.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier Science Inc 2023
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10265134/ https://www.ncbi.nlm.nih.gov/pubmed/36997003 http://dx.doi.org/10.1016/j.peptides.2023.171003

Ejemplares similares

Revisiting the Pharmacological Value of Glucagon: An Editorial for the Special Issue “The Biology and Pharmacology of Glucagon”
por: Müller, Timo D., et al.
Publicado: (2020)

Glucagon-like Peptide-1 Receptor Agonists in the Management of Type 2 Diabetes Mellitus and Obesity: The Impact of Pharmacological Properties and Genetic Factors
por: Klen, Jasna, et al.
Publicado: (2022)

Repositioning Glucagon Action in the Physiology and Pharmacology of Diabetes
por: Finan, Brian, et al.
Publicado: (2020)

Glucagon‐like peptide‐1 receptor agonist prescribing patterns in adolescents with type 2 diabetes
por: Bensignor, Megan O., et al.
Publicado: (2022)

Predictors of Effectiveness of Glucagon-Like Peptide-1 Receptor Agonist Therapy in Patients with Type 2 Diabetes and Obesity
por: Babenko, Alina Yu., et al.
Publicado: (2019)

Glucagon-like peptide-1 and glucagon-like peptide-1 receptor agonists in the treatment of type 2 diabetes
por: Lee, Seungah, et al.
Publicado: (2017)

Conformation Transition of Intracellular Part of Glucagon Receptor in Complex With Agonist Glucagon by Conventional and Accelerated Molecular Dynamics Simulations
por: Bai, Qifeng, et al.
Publicado: (2019)

Glucagon-Like Peptide 1 Receptor Agonists for Type 2 Diabetes
por: Hinnen, Deborah
Publicado: (2017)

GLP-1/glucagon receptor co-agonism for treatment of obesity
por: Sánchez-Garrido, Miguel A., et al.
Publicado: (2017)

It Is Time to Consider Glucagon-Like Peptide-1 Receptor Agonists for the Treatment of Type 2 Diabetes in Youth
por: Oberle, Megan M., et al.
Publicado: (2019)

Receptor occupancy of dual glucagon-like peptide 1/glucagon receptor agonist SAR425899 in individuals with type 2 diabetes
por: Eriksson, Olof, et al.
Publicado: (2020)

Next generation GLP-1/GIP/glucagon triple agonists normalize body weight in obese mice
por: Knerr, Patrick J., et al.
Publicado: (2022)

Effects of glucagon-like peptide-1 receptor agonists on glucose excursion and inflammation in overweight or obese type 2 diabetic patients
por: Huang, Xiao-Min, et al.
Publicado: (2023)

Glucagon-like Peptide-1 Receptor Agonists for the Treatment of Type 2 Diabetes in Youth
por: Berman, Casey, et al.
Publicado: (2023)

Is there a role for glucagon-like peptide-1 receptor agonists in the management of diabetic nephropathy?
por: Veneti, Stavroula, et al.
Publicado: (2020)

Glucagon-like Peptide-1 Receptor Agonist Treatment With Semaglutide in Type 1 Diabetes
por: Raven, Lisa M, et al.
Publicado: (2022)

Sex Differences in Response to Treatment with Glucagon-like Peptide 1 Receptor Agonists: Opportunities for a Tailored Approach to Diabetes and Obesity Care
por: Rentzeperi, Elpiniki, et al.
Publicado: (2022)

Pharmacological targeting of α3β4 nicotinic receptors improves peripheral insulin sensitivity in mice with diet-induced obesity
por: Jall, Sigrid, et al.
Publicado: (2020)

Glucagon Regulation of Energy Expenditure
por: Kleinert, Maximilian, et al.
Publicado: (2019)

Glucagon-Like Peptide-1 Receptor Agonist Semaglutide Improves Eating Behavior and Glycemic Control in Japanese Obese Type 2 Diabetic Patients
por: Masaki, Takayuki, et al.
Publicado: (2022)

Clinical Application of Glucagon-Like Peptide 1 Receptor Agonists for the Treatment of Type 2 Diabetes Mellitus
por: Cho, Young Min, et al.
Publicado: (2013)

Review article: role of glucagon‐like peptide‐1 receptor agonists in non‐alcoholic steatohepatitis, obesity and diabetes—what hepatologists need to know
por: Barritt, A. Sidney, et al.
Publicado: (2022)

Cardiovascular Effects of Glucagon-Like Peptide-1 Receptor Agonists
por: Kang, Yu Mi, et al.
Publicado: (2016)

Improved postprandial glucose metabolism in type 2 diabetes by the dual glucagon‐like peptide‐1/glucagon receptor agonist SAR425899 in comparison with liraglutide
por: Schiavon, Michele, et al.
Publicado: (2021)

Reversal of Obesity and Insulin Resistance by a Non-Peptidic Glucagon-Like Peptide-1 Receptor Agonist in Diet-Induced Obese Mice
por: He, Min, et al.
Publicado: (2010)

Insulin–glucagon‐like peptide‐1 receptor agonist relay and glucagon‐like peptide‐1 receptor agonist first regimens in individuals with type 2 diabetes: A randomized, open‐label trial study
por: Takeshita, Yumie, et al.
Publicado: (2022)

Molecular Characterisation of Small Molecule Agonists Effect on the Human Glucagon Like Peptide-1 Receptor Internalisation
por: Thompson, Aiysha, et al.
Publicado: (2016)

Effects of glucagon-like peptide 1 receptor agonists on comorbidities in older patients with diabetes mellitus
por: Onoviran, Olusola F., et al.
Publicado: (2019)

Long-term management of type 2 diabetes with glucagon-like peptide-1 receptor agonists
por: Courtney, Hamish, et al.
Publicado: (2017)

Glucagon-Like Peptide-1 Receptor Agonists in Type 2 Diabetes: Their Use and Differential Features
por: Lyseng-Williamson, Katherine A.
Publicado: (2019)

The Effect of Glucagon-Like Peptide-1 Receptor Agonists on Renal Outcomes in Type 2 Diabetes
por: Yin, Win L., et al.
Publicado: (2020)

Asthma Exacerbations in Individuals on Glucagon-like Peptide-1 Receptor Agonists for Type 2 Diabetes
por: Watchorn, David, et al.
Publicado: (2021)

Correction to “Glucagon-like Peptide-1 Receptor Agonist Treatment With Semaglutide in Type 1 Diabetes”
Publicado: (2022)

Clinical Impact of Semaglutide, a Glucagon-Like Peptide-1 Receptor Agonist, on Obesity Management: A Review
por: Alorfi, Nasser M, et al.
Publicado: (2022)

How glucagon-like peptide 1 receptor agonists work
por: Andreasen, Christine Rode, et al.
Publicado: (2021)

Efficacy and safety profile of Glucagon-Like Peptide-1 Receptor Agonist in obese Type-2 diabetes patients from a private institution in Karachi
por: Qasim, Saeeda Fouzia, et al.
Publicado: (2023)

An Effective Glucagon-Like Peptide-1 Receptor Agonists, Semaglutide, Improves Sarcopenic Obesity in Obese Mice by Modulating Skeletal Muscle Metabolism
por: Ren, Qingjuan, et al.
Publicado: (2022)

Monomeric GLP-1/GIP/glucagon triagonism corrects obesity, hepatosteatosis, and dyslipidemia in female mice
por: Jall, Sigrid, et al.
Publicado: (2017)

Glucagon-like peptide-1 receptor agonists and diabetic retinopathy: nationwide cohort and Mendelian randomization studies
por: Zheng, Deqiang, et al.
Publicado: (2023)

Design of Glucagon-Like Peptide-1 Receptor Agonist for Diabetes Mellitus from Traditional Chinese Medicine
por: Tang, Hsin-Chieh, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_cukmnp4hgt9tdk3pftuah1haqk